Schrodinger Inc

Quantum computing and artificial intelligence are breaking down barriers in the global pharmaceutical industry. By simulating molecules at the subatomic level on computers, they slash drug discovery timelines from an average of 10 to 15 years down to just months, saving tens of billions of dollars in costs. Major pharmaceutical companies are turning to advanced computing power through platforms from infrastructure providers like Schrödinger and NVIDIA, two key case studies that dominate this infrastructure. Schrödinger is a leader in molecular physics simulation software, developed over 30 years, generating revenue from both SaaS software and drug discovery services. Meanwhile, NVIDIA has launched BioNeMo, a cloud-based generative AI platform specifically for drug development, locking in the ecosystem from GPU hardware to enterprise software. Investing in this theme means investing in the platforms and software that global drug companies must use, reducing the traditional risks of biotech stocks and aligning with major global trends through a safer risk structure.

Schrödinger, Inc. reported second-quarter 2026 revenue of US$58.89 million and a shift to a US$5.98 million net profit, while expanding its collaboration with Bristol Myers Squibb to deploy its agentic AI co-scientist, Bunsen, across the partner's research organization. The expanded Bunsen agreement connects Schrödinger's new AI tool to a large existing customer, reinforcing the catalyst around deeper usage within top accounts and broader AI module adoption. Alongside the earnings turnaround, the company also highlighted an ESOP shelf registration that ties employee incentives to the success of Bunsen and related AI offerings. The investment narrative projects US$349.6 million in revenue and US$23.4 million in earnings by 2029, requiring 11.1% yearly revenue growth and a US$126.9 million earnings increase from a current loss of US$103.5 million. The biggest risk remains whether higher-value software adoption can offset ongoing margin pressures and volatile collaboration income.

Schrödinger has entered a strategic collaboration and software agreement with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organization. The deal significantly expands BMS's use of Schrödinger's computational platform, enabling scientists to explore more possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions. The collaboration includes developing novel functionality within Bunsen alongside Schrödinger's computational technologies for large-scale chemical exploration and its AI-driven synthesis planning platform RetroSynth. Bunsen is optimized to execute Schrödinger's validated, physics-based computational platform by planning and running complex molecular discovery workflows and interpreting results. BMS, a long-standing customer, will adopt Bunsen at scale, empowering a broader group of scientists to embrace a predict-first computational approach.

Schrödinger announced the early access launch of Bunsen, an agentic AI co-scientist designed to help researchers plan, execute, and interpret complex molecular discovery workflows. Bunsen combines AI with physics-based simulation to let scientists evaluate more hypotheses and explore chemical space more efficiently, making advanced computational methods accessible even to drug hunters who are not computational chemists. The launch is supported by Schrödinger's collaborations with NVIDIA and Google Cloud, which will provide a co-engineered full stack AI platform including NVIDIA BioNeMo Agent Toolkit and NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs, along with Google Cloud's elastic computing infrastructure. Early access is available now to select customers, with full commercial release expected by the end of 2026.

Investment in AI-driven drug discovery has surged past $2 billion as the technology cuts development timelines by 70% and doubles clinical success rates, according to a new BCC Research report. The report finds that AI reduces the traditional 4-to-5-year discovery phase to 12-to-18 months while lowering R&D costs by 30% to 40%. AI-validated targets show a 2.5 times greater probability of progressing through clinical development, with regulatory approval rates rising from 10-to-15% to 20%. The United States accounts for 60% of global investment, with major funding rounds including Generate: Biomedicines at over $500 million, Exscientia at over $500 million, and Kailera Therapeutics with a $600 million Series B. Key players include Atomwise, Exscientia, Generate: Biomedicines, Iambic Therapeutics, Recursion, Schrödinger, Insilico Medicine, and Benevolent AI, alongside pharmaceutical giants Pfizer and Bayer.

Artificial intelligence is reshaping drug discovery by cutting development timelines from years to weeks, targeting a pipeline where 90% of candidates fail to reach approval. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 revenue, a 215% increase, while Novo Nordisk's GLP-1 portfolio reached $34.6 billion. Schrodinger's physics-based simulation software serves 18 of the world's 20 largest pharma companies and posted 12% revenue growth in Q1 2026. AI is particularly suited to peptide-based medicines, enabling faster discovery and more precise molecular design. Investors can gain exposure through established leaders like Eli Lilly and Novo Nordisk, or through AI-focused platforms such as Schrodinger and Recursion Pharmaceuticals.

Schrodinger Inc reported a 12% year-over-year increase in annual contract value to $28.4 million in its first-quarter 2026 results, driven by new deployments and usage scale-ups. The company is transitioning its platform to a hosted software licensing model, which contributed to a 21% decline in software revenue, while drug discovery revenue more than doubled to $22.9 million due to progress in its collaboration portfolio. For the second quarter of 2026, Schrodinger anticipates annual contract value between $19 million and $23 million, and for the full year it expects annual contract value in the range of $218 million to $228 million, reflecting growth of 10% to 15%. The company also projects full-year drug discovery revenue between $55 million and $65 million. Schrodinger also announced a separation agreement with former Chief Commercial Officer Mannix Aklian.